AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03674060
Drug: Nexavar tab
RxNorm normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nexavar 200mg/tablet, PO, 1 tablet
Trial: NCT00563147
Drug: tivozanib (AV-951) plus temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
Trial: NCT00006294
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participant's drug dose will be titrated from 10mg to 40mg over the course of the study
Trial: NCT00006294
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participant's drug dose will be titrated from 10mg to 40mg over the course of the study
Trial: NCT00006294
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participant's drug dose will be titrated from 2mg to 8mg over the course of the study
Trial: NCT01217060
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
Trial: NCT01217060
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
Trial: NCT01217060
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg IV 30 minutes prior to weekly Docetaxel.
Trial: NCT00004888
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02082210
Drug: Emibetuzumab
RxNorm normalized name: Emibetuzumab
DrugBank: Emibetuzumab (DB11849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously (IV)
Trial: NCT02082210
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered Intravenously (IV)
Trial: NCT02397330
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02397330
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00621881
Drug: naproxcinod
RxNorm normalized name: Naproxcinod
DrugBank: Naproxcinod (DB06682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg bid
Trial: NCT02174848
Drug: Deferiprone oral solution
RxNorm normalized name: deferiprone Oral Solution
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
Trial: NCT00705978
Drug: Pancreatin
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
Trial: NCT00254566
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 X 400mg capsule once daily for 5 days
Trial: NCT02094716
Drug: Permethrin Foam 4%
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application, whole-body treatment
Trial: NCT02094716
Drug: Permethrin Foam 5%
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application, whole-body treatment
Trial: NCT02094716
Drug: Vehicle Foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application, whole-body treatment
Trial: NCT00902564
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Trial: NCT00116831
Drug: Glipizide
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral anti-diabetic medication
Trial: NCT00116831
Drug: rosiglitazone maleate
RxNorm normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral antidiabetic medication
Trial: NCT03616912
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT02130063
Drug: iron isomaltoside 1000 (Monofer®)
RxNorm normalized name: ferric carboxymaltose
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02130063
Drug: iron sucrose (Venofer®)
RxNorm normalized name: iron sucrose Injection [Venofer]
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02418468
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol 150µg capsules for inhalation daily
Trial: NCT01232296
Drug: dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg p.o. o.d. 5 days on/2 days off
Trial: NCT01232296
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg p.o. b.i.d.
Trial: NCT04054687
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
Trial: NCT00151814
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
Trial: NCT03047109
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
Trial: NCT03047109
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
Trial: NCT00017264
Drug: atrasentan hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02174835
Drug: AVP-786
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02174835
Drug: AVP-923
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01110746
Drug: LISPRO
RxNorm normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100IU/mL administered subcutaneously
Trial: NCT03249285
Drug: Peri
RxNorm normalized name: Peri-DS
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
Trial: NCT03249285
Drug: HCTZ
RxNorm normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
Trial: NCT01214486
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
Trial: NCT01451775
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: high dose of empagliflozin after overnight fasting for at least 10 h
Trial: NCT01451775
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: low dose empagliflozin after overnight fasting for at least 10 h
Trial: NCT01451775
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: high dose of empagliflozin after a standardised high fat breakfast
Trial: NCT02932904
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vortioxetine Overencapsulated Tablet
Trial: NCT02932904
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine Overencapsulated Tablets.
Trial: NCT01488097
Drug: sebelipase alfa
RxNorm normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Trial: NCT00699010
Drug: Oxycodone 5mg taken first
RxNorm normalized name: oxycodone 13.5 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: followed by Acurox 5/30mg with 48 hour washout
Trial: NCT01263548
Drug: lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
Trial: NCT00630968
Drug: Levetiracetam (Keppra)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03805022
Drug: Ifosfamide or dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
Trial: NCT03805022
Drug: Ifosfamide or dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
Trial: NCT00702117
Drug: flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg iv in 10 minutes
Trial: NCT00702117
Drug: ajmaline
RxNorm normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg iv in 10 minutes
Trial: NCT00702117
Drug: procainamide
RxNorm normalized name: Procainamide
DrugBank: Procainamide (DB01035)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg iv in 10 minutes
Trial: NCT01966965
Drug: NEDAX
RxNorm normalized name: Nedocromil
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AS SPECIFIED AT THE LEAFLET
Trial: NCT03786757
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Trial: NCT03987893
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
Trial: NCT00311896
Drug: Bemiparin
RxNorm normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03437785
Drug: CKD-495 75mg
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-495 75mg Tab.
Trial: NCT03437785
Drug: CKD-495 150mg
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-495 150mg Tab.
Trial: NCT03437785
Drug: Rebamipide 100mg
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide 100mg Tab.
Trial: NCT03437785
Drug: Placebo of the Rebamipide 100mg
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Placebo of the Rebamipide 100mg Tab
Trial: NCT01212718
Drug: systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
Trial: NCT03908944
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
Trial: NCT03880903
Drug: normal saline and salbutamol
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
Trial: NCT00793338
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20mg three times a day for 3 months.
Trial: NCT01364428
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted.
Trial: NCT01952756
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet (100 mg) twice per day for 12 weeks
Trial: NCT03967392
Drug: Xylocaine
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TREATMENT
Trial: NCT00716911
Drug: ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03042052
Drug: detrusor infection of Botulinum toxin
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: detrusor injection
Trial: NCT01141881
Drug: Tissue Plasminogen Activator,bevacizumab ,follow up
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
Trial: NCT03917420
Drug: Tenofovir 300Mg Oral Tablet
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily dose of the combo tab x 5 days pre-sampling
Trial: NCT03917420
Drug: Emtricitabine 200 MG
RxNorm normalized name: emtricitabine 200 MG
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily dose of the combo tab x 5 days pre-sampling
Trial: NCT02758392
Drug: JNJ-61178104 Intravenous
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.
Trial: NCT02758392
Drug: JNJ-61178104 Subcutaneous
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-61178104 Subcutaneously on Day 1.
Trial: NCT00801125
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02689258
Drug: Bupivicaine HCl
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl via injection
Trial: NCT03373383
Drug: Padsevonil
RxNorm normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Padsevonil in different dosages.
Trial: NCT00500422
Drug: Doxil
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
Trial: NCT00500422
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
Trial: NCT00500422
Drug: Velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
Trial: NCT01250587
Drug: PDC31
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
Trial: NCT03823248
Drug: Sanchi powder
RxNorm normalized name: Sanchi
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
Trial: NCT03823248
Drug: MoLuoDan simulation
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
Trial: NCT03823248
Drug: Sanchi powder simulation
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
Trial: NCT03765645
Drug: Piperacillin + Tazobactam
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
Trial: NCT02308644
Drug: intravitreal bevacizumab injection(1.25mg)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal bevacizumab injection(1.25mg) / Sham injection
Trial: NCT00893516
Drug: CHOP
RxNorm normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00917436
Drug: Thiocolchicoside
RxNorm normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168350
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01899599
Drug: PankoMab-GEX
RxNorm normalized name: Immunoglobulin g1, anti-(mucin muc1) (human-mus musculus monoclonal pankomab-gex heavy chain), disulfide with human-mus musculus monoclonal pankomab-gex light chain, dimer
DrugBank: Gatipotuzumab (DB18861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01725191
Drug: Tivantinib
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04372602
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: -For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
Trial: NCT00736801
Drug: Salmeterol and Salmeterol / Fluticasone
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.